Pharmacovigilance Risk Assessment Committee (PRAC) recommend restrictions in use of cyproterone due to meningioma (non-cancerous brain tumour) risk

PRAC has recommended that medicines with daily doses of ≥ 10 mg of cyproterone should only be used for androgen-dependent conditions e.g. hirsutism, alopecia, acne and seborrhoea; once other treatment options including treatment with lower doses have failed.


European Medicines Agency